| For: | Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5512-5518 [PMID: 18810768 DOI: 10.3748/wjg.14.5512] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i36/5512.htm |
| Number | Citing Articles |
| 1 |
P. C. Church, D. Turner, B. M. Feldman, T. D. Walters, M.‐L. Greer, M. M. Amitai, A. M. Griffiths. Systematic review with meta‐analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease. Alimentary Pharmacology & Therapeutics 2015; 41(2) doi: 10.1111/apt.13024
|
| 2 |
Fernando Gomollón, Javier P. Gisbert. ¿Es necesario asociar inmunomoduladores al tratamiento biológico en la enfermedad inflamatoria intestinal?. Gastroenterología y Hepatología 2010; 33(1) doi: 10.1016/j.gastrohep.2009.03.008
|
| 3 |
Balakrishnan S. Ramakrishna, Govind K. Makharia, Philip Abraham, Uday C. Ghoshal, Venkataraman Jayanthi, Brij Kishore Agarwal, Vineet Ahuja, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra C. Desai, Gopal Krishna Dhali, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Ajay Kumar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S. Puri, Ganesh N. Ramesh, Gautam Ray, Shivaram P. Singh, Ajit Sood, Manu Tandan. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian Journal of Gastroenterology 2012; 31(6) doi: 10.1007/s12664-012-0259-0
|
| 4 |
Lorenz Grob, Sena Bluemel, Luc Biedermann, Nicolas Fournier, Jean-Benoit Rossel, Stephan R. Vavricka, Jonas Zeitz, Gerhard Rogler, Andreas Stallmach, Michael Scharl. Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284819895217
|
| 5 |
J.V. Arcos-Machancoses, E. Donat-Aliaga, B. Polo-Miquel, E. Masip-Simó, C. Ribes-Koninckx, A. Pereda-Pérez. Retraso diagnóstico en la enfermedad inflamatoria intestinal pediátrica. Descripción y estudio de los factores de riesgo. Anales de Pediatría 2015; 82(4) doi: 10.1016/j.anpedi.2014.05.024
|
| 6 |
Stephan R. Vavricka, Sabrina M. Spigaglia, Gerhard Rogler, Valérie Pittet, Pierre Michetti, Christian Felley, Christian Mottet, Christian P. Braegger, Daniela Rogler, Alex Straumann, Peter Bauerfeind, Michael Fried, Alain M. Schoepfer. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases 2012; 18(3) doi: 10.1002/ibd.21719
|
| 7 |
Makoto Naganuma, Atsushi Sakuraba, Toshifumi Hibi. Ulcerative colitis: prevention of relapse. Expert Review of Gastroenterology & Hepatology 2013; 7(4) doi: 10.1586/egh.13.18
|
| 8 |
Cristina Ribeiro de Barros Cardoso, Amanda de Castro Habka, Camila Figueiredo Pinzan, Camilla Narjara Simão Oliveira, Jefferson Luiz da Silva, Murillo Duarte-Silva. Biological Therapy for Inflammatory Bowel Disease. 2020; doi: 10.5772/intechopen.90009
|
| 9 |
J.V. Arcos-Machancoses, E. Donat-Aliaga, B. Polo-Miquel, E. Masip-Simó, C. Ribes-Koninckx, A. Pereda-Pérez. Description and study of risk factors for the diagnostic delay of paediatric inflammatory bowel disease. Anales de Pediatría (English Edition) 2015; 82(4) doi: 10.1016/j.anpede.2015.03.004
|
| 10 |
Ho Suk Kang, Ja Seol Koo, Kang Moon Lee, Dae Bum Kim, Ji Min Lee, Yoon Jae Kim, Hyuk Yoon, Hyun Joo Jang. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World Journal of Gastroenterology 2019; 25(8): 989-1001 doi: 10.3748/wjg.v25.i8.989
|
| 11 |
Manuel Barreiro-de Acosta, Fernando Magro, Daniel Carpio, Paula Lago, Ana Echarri, José Cotter, Santos Pereira, Raquel Gonçalves, Aurelio Lorenzo, Laura Carvalho, Javier Castro, Luisa Barros, Jorge Amil Dias, Susana Rodrigues, Francisco Portela, Camila Dias, Altamiro da Costa-Pereira. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflammatory Bowel Diseases 2010; 16(7) doi: 10.1002/ibd.21170
|
| 12 |
Deepa K. Ingawale, Satish K. Mandlik, Suresh R. Naik. Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s): A critical discussion. Environmental Toxicology and Pharmacology 2014; 37(1) doi: 10.1016/j.etap.2013.08.015
|
| 13 |
Kalle Landerholm, Disa Kalman, Conny Wallon, Pär Myrelid. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease?. Current Drug Targets 2019; 20(13) doi: 10.2174/1389450120666190617163919
|
| 14 |
|
| 15 |
Alain M. Schoepfer, Stephan Vavricka, Ekaterina Safroneeva, Nicolas Fournier, Christine Manser, Pascal Frei, Pierre Deltenre, Gerhard Rogler, Alex Straumann, Jessica Ezri, Andreas Nydegger, Christian Braegger. Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2017; 64(2) doi: 10.1097/MPG.0000000000001238
|
| 16 |
Andrea Cossu, Livia Biancone, Marta Ascolani, Francesco Pallone, Monica Boirivant. “In vitro” azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. Journal of Crohn's and Colitis 2013; 7(6) doi: 10.1016/j.crohns.2012.06.020
|
| 17 |
Susann Hasler, Nadine Zahnd, Salomé Müller, Stephan Vavricka, Gerhard Rogler, Ryan Tandjung, Thomas Rosemann. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. BMJ Open 2015; 5(3) doi: 10.1136/bmjopen-2014-007306
|
| 18 |
Sandro Ardizzone, Andrea Cassinotti, Gianpiero Manes, Gabriele Bianchi Porro. Review: Immunomodulators for all patients with inflammatory bowel disease?. Therapeutic Advances in Gastroenterology 2010; 3(1) doi: 10.1177/1756283X09354136
|
| 19 |
Laurent Peyrin-Biroulet, Gionata Fiorino, Anthony Buisson, Silvio Danese. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. Nature Reviews Gastroenterology & Hepatology 2013; 10(6) doi: 10.1038/nrgastro.2013.31
|
| 20 |
Alain M Schoepfer, Mohamed-Ali Dehlavi, Nicolas Fournier, Ekaterina Safroneeva, Alex Straumann, Valérie Pittet, Laurent Peyrin-Biroulet, Pierre Michetti, Gerhard Rogler, Stephan R Vavricka. Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. American Journal of Gastroenterology 2013; 108(11) doi: 10.1038/ajg.2013.248
|
| 21 |
Antony Aziz, Rebecca Reynolds, Azhar Ansari. Process and Systems: A population-based model of care for people with inflammatory bowel disease – patient-reported outcomes. Future Healthcare Journal 2019; 6(1) doi: 10.7861/futurehosp.6-1-30
|
| 22 |
Pearl Avery. The cost of treating inflammatory bowel disease: step-up vs step-down, therapeutic drug monitoring and personalised medicine. Gastrointestinal Nursing 2021; 19(4) doi: 10.12968/gasn.2021.19.4.18
|
| 23 |
Giovanni C Actis, Rinaldo Pellicano, Mario Rizzetto, Muhammad Ayoubi, Nicola Leone, Gianfranco Tappero, Paola Pazienza, Floriano Rosina. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World Journal of Gastroenterology 2009; 15(12): 1420-1426 doi: 10.3748/wjg.15.1420
|
| 24 |
J.M. Marugán de Miguelsanz, S. Abad Arevalillo, P. Redondo del Río, M. Marcos Temprano. ¿Cómo debemos actuar en pacientes con colitis ulcerosa e infección por citomegalovirus?. Anales de Pediatría 2014; 80(2) doi: 10.1016/j.anpedi.2013.04.014
|
| 25 |
Tarsila Campanha da Rocha Ribeiro, Liliana Andrade Chebli, Pedro Duarte Gaburri, Julio Maria Fonseca Chebli. Azathioprine in ulcerative colitis: Why, when, how and how long to use it. Drug Development Research 2011; 72(8) doi: 10.1002/ddr.20481
|
| 26 |
Gokhan Okan, Pervin Vural, Onder Peker, Emel Colakoglu, Murat Saruc. Azathioprine-induced liver injury in a patient with multiple autoimmune syndrome. Journal of Dermatological Treatment 2010; 21(6) doi: 10.3109/09546630903410174
|
| 27 |
Maggie Lee, Jennifer Kovacs-Nolan, Tania Archbold, Ming Z. Fan, Lekh R. Juneja, Tutomu Okubo, Yoshinori Mine. Therapeutic potential of hen egg white peptides for the treatment of intestinal inflammation. Journal of Functional Foods 2009; 1(2) doi: 10.1016/j.jff.2009.01.005
|
| 28 |
Choon Jin Ooi, Kwong Ming Fock, Govind K Makharia, Khean Lee Goh, Khoon Lin Ling, Ida Hilmi, Wee Chian Lim, Thia Kelvin, Peter R Gibson, Richard B Gearry, Qin Ouyang, Jose Sollano, Sathaporn Manatsathit, Rungsun Rerknimitr, Shu‐chen Wei, Wai Keung Leung, H Janaka De Silva, Rupert WL Leong. The Asia‐Pacific consensus on ulcerative colitis. Journal of Gastroenterology and Hepatology 2010; 25(3) doi: 10.1111/j.1440-1746.2010.06241.x
|
| 29 |
Qiufang Liang, Xiaofeng Ren, Meram Chalamaiah, Haile Ma. Simulated gastrointestinal digests of corn protein hydrolysate alleviate inflammation in caco-2 cells and a mouse model of colitis. Journal of Food Science and Technology 2020; 57(6) doi: 10.1007/s13197-020-04242-7
|
| 30 |
Giulia Straforini, Ramona Brugnera, Rosy Tambasco, Fernando Rizzello, Paolo Gionchetti, Massimo Campieri. Attualità e controversie nella terapia delle malattie infiammatorie croniche intestinali. Italian Journal of Medicine 2009; 3(3) doi: 10.1016/j.itjm.2009.02.001
|
| 31 |
Jacob Tveiten Bjerrum, Yulan Wang, Fuhua Hao, Mehmet Coskun, Christian Ludwig, Ulrich Günther, Ole Haagen Nielsen. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn’s disease and healthy individuals. Metabolomics 2015; 11(1) doi: 10.1007/s11306-014-0677-3
|
| 32 |
Jacques Cosnes, Philippe Seksik. Early Azathioprine in Crohnʼs Disease. Inflammatory Bowel Diseases 2013; 19(3) doi: 10.1097/MIB.0b013e318281d697
|